259 related articles for article (PubMed ID: 30419425)
1. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
Gaitán MI; Ysrraelit MC; Correale J
JAMA Neurol; 2017 Sep; 74(9):1143-1144. PubMed ID: 28715536
[No Abstract] [Full Text] [Related]
3. Case Report: Delayed Alemtuzumab-Induced Concurrent Neutropenia and Thrombocytopenia in Relapsing-Remitting Multiple Sclerosis.
Ganju A; Stock JC; Jordan K
J Pharm Pract; 2023 Feb; 36(1):168-172. PubMed ID: 34169768
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
Aitken L; Patel R; D'Rozario J; Choi P
Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
[TBL] [Abstract][Full Text] [Related]
5. A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.
Vakrakou AG; Tzanetakos D; Valsami S; Grigoriou E; Psarra K; Tzartos J; Anagnostouli M; Andreadou E; Evangelopoulos ME; Koutsis G; Chrysovitsanou C; Gialafos E; Dimitrakopoulos A; Stefanis L; Kilidireas C
BMC Neurol; 2018 Oct; 18(1):178. PubMed ID: 30373566
[TBL] [Abstract][Full Text] [Related]
6. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
7. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
8. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
Alamo A; Condorelli RA; La Vignera S; Calogero AE
Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
[TBL] [Abstract][Full Text] [Related]
10. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab-associated diffuse alveolar damage - a case report.
Bayas A; Menacher M; Schwaiblmair M; Märkl B; Naumann M
BMC Neurol; 2020 Sep; 20(1):357. PubMed ID: 32967641
[TBL] [Abstract][Full Text] [Related]
12. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
[TBL] [Abstract][Full Text] [Related]
14. Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report.
Liou AA; Skiver BM; Yates E; Persad P; Meyer D; Farland AM; Rocco MV
Am J Kidney Dis; 2019 May; 73(5):615-619. PubMed ID: 30528935
[TBL] [Abstract][Full Text] [Related]
15. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
Ranganathan U; Kaunzner U; Foster S; Vartanian T; Perumal JS
Mult Scler; 2018 Apr; 24(4):540-542. PubMed ID: 28287030
[TBL] [Abstract][Full Text] [Related]
16. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune storm following alemtuzumab.
Chan C; Beauchemin P; Sayao AL; Carruthers M
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
[TBL] [Abstract][Full Text] [Related]
18. Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.
Adamec I; Mayer M; Ćorić M; Ruška B; Habek M
Mult Scler Relat Disord; 2020 Nov; 46():102589. PubMed ID: 33296985
[TBL] [Abstract][Full Text] [Related]
19. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
[TBL] [Abstract][Full Text] [Related]
20. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
Gao J; Jones J; Damato EM; Coles A
J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387
[No Abstract] [Full Text] [Related]
[Next] [New Search]
